Voyager Therapeutics PE Ratio 2014-2022 | VYGR
Current and historical p/e ratio for Voyager Therapeutics (VYGR) from 2014 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Voyager Therapeutics PE ratio as of May 27, 2022 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Voyager Therapeutics PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2022-05-27 |
6.05 |
|
0.00 |
| 2022-03-31 |
7.62 |
$-1.88 |
0.00 |
| 2021-12-31 |
2.71 |
$-1.90 |
0.00 |
| 2021-09-30 |
2.63 |
$-2.48 |
0.00 |
| 2021-06-30 |
4.13 |
$0.46 |
8.98 |
| 2021-03-31 |
4.71 |
$1.03 |
4.57 |
| 2020-12-31 |
7.15 |
$0.95 |
7.53 |
| 2020-09-30 |
10.67 |
$1.04 |
10.26 |
| 2020-06-30 |
12.62 |
$-1.64 |
0.00 |
| 2020-03-31 |
9.15 |
$-1.12 |
0.00 |
| 2019-12-31 |
13.95 |
$-1.27 |
0.00 |
| 2019-09-30 |
17.21 |
$-1.63 |
0.00 |
| 2019-06-30 |
27.22 |
$-1.85 |
0.00 |
| 2019-03-31 |
19.14 |
$-2.94 |
0.00 |
| 2018-12-31 |
9.40 |
$-2.76 |
0.00 |
| 2018-09-30 |
18.92 |
$-2.46 |
0.00 |
| 2018-06-30 |
19.54 |
$-2.72 |
0.00 |
| 2018-03-31 |
18.79 |
$-2.65 |
0.00 |
| 2017-12-31 |
16.60 |
$-2.67 |
0.00 |
| 2017-09-30 |
20.59 |
$-2.84 |
0.00 |
| 2017-06-30 |
8.96 |
$-2.30 |
0.00 |
| 2017-03-31 |
13.24 |
$-1.94 |
0.00 |
| 2016-12-31 |
12.74 |
$-1.58 |
0.00 |
| 2016-09-30 |
12.01 |
$-1.68 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.233B |
$0.037B |
|
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
|
